Key Findings
- The 2024 analysis included 35 trials and 58,937 participants; 800-1,000 IU/day was associated with lower fall risk than placebo or no treatment (RR 0.85, 95% CI 0.74-0.95).
- Doses above 1,000 IU/day had a higher fall risk than the 800-1,000 IU/day group in that network analysis. This comparison does not mean every dose above 1,000 IU increases falls compared with placebo.
- In the 2024 subgroup analysis, daily 800-1,000 IU regimens had RR 0.78 (95% CI 0.64-0.92); intermittent regimens had no preventive effect.
- For baseline 25(OH)D at or below 50 nmol/L, the 2024 analysis reported RR 0.69 (95% CI 0.52-0.86); the higher-status subgroup did not show a significant reduction.
- The 2022 review included 38 trials and 61,350 participants. For doses at least 700 IU/day it reported RR 0.87 (95% CI 0.79-0.96) and an absolute risk difference of -0.06. Its conclusion covered 700-2,000 IU/day and cautioned that outcome differences were small.